👍👍👍_老虎社区_美港股上老虎

Champion365
2021-11-08

👍👍👍

Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis

ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glauco

Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":845544162,"tweetId":"845544162","gmtCreate":1636355721783,"gmtModify":1636355722581,"author":{"id":3573653602271971,"authorId":3573653602271971,"authorIdStr":"3573653602271971","name":"Champion365","avatar":"https://static.tigerbbs.com/04df800589718231e24e96f7a0b551cc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":54,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍👍👍</p></body></html>","htmlText":"<html><head></head><body><p>👍👍👍</p></body></html>","text":"👍👍👍","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/845544162","repostId":1165168470,"repostType":4,"repost":{"id":"1165168470","pubTimestamp":1636354224,"share":"https://www.laohu8.com/m/news/1165168470?lang=&edition=full","pubTime":"2021-11-08 14:50","market":"us","language":"en","title":"Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis","url":"https://stock-news.laohu8.com/highlight/detail?id=1165168470","media":"Reuters","summary":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glauco","content":"<p>ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.</p>\n<p>Privately held Ivantis Hydrus Microstent makes a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery.</p>\n<p>The microstent, roughly the size of an eyelash, reduces eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway, Alcon said.</p>\n<p>Glaucoma is the second-largest cause of blindness after cataracts, affecting more than 75 million people globally, it added.</p>\n<p>The Swiss company, which spun off from Novartis in 2019, said the deal for California-based Ivantis strengthened its portfolio of treatments for cataract, refractive, retina and glaucoma patients.</p>\n<p>It cited a study showed 65% of Hydrus Microstent patients remained medication-free at five years after having the stent implanted.</p>\n<p>Alcon said it may be required to make additional payments upon the achievement of certain regulatory and commercial milestones.</p>\n<p>The transaction is anticipated to close in the first quarter of 2022 subject to customary closing conditions, including regulatory approval, it added.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon agrees $475 million deal to buy U.S. eye surgery company Ivantis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 14:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.\nPrivately held Ivantis ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALC":"爱尔康"},"source_url":"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165168470","content_text":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.\nPrivately held Ivantis Hydrus Microstent makes a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery.\nThe microstent, roughly the size of an eyelash, reduces eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway, Alcon said.\nGlaucoma is the second-largest cause of blindness after cataracts, affecting more than 75 million people globally, it added.\nThe Swiss company, which spun off from Novartis in 2019, said the deal for California-based Ivantis strengthened its portfolio of treatments for cataract, refractive, retina and glaucoma patients.\nIt cited a study showed 65% of Hydrus Microstent patients remained medication-free at five years after having the stent implanted.\nAlcon said it may be required to make additional payments upon the achievement of certain regulatory and commercial milestones.\nThe transaction is anticipated to close in the first quarter of 2022 subject to customary closing conditions, including regulatory approval, it added.","news_type":1},"isVote":1,"tweetType":1,"viewCount":603,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}